Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01929577 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01929577 is a Phase 1 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 36 participants.
The verdict
NCT01929577, a Phase 1 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the relative bioavailability of ASP015K under fasting conditions after single-dose administration between a test-tablet formulation and a reference-tablet formulation. This study will also evaluate the food effect on bioavailability of the test formulation, and evaluate the safety and tolerability after single-dose administration of the test- and reference-tablet formulations.
Interventions
- DRUG ASP015K
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01929577
The ClinicalTrials.gov registry entry for NCT01929577 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASP015K is the first listed.
NCT01929577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01929577 about?
NCT01929577 is a clinical study titled "A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects". The purpose of this study is to determine the relative bioavailability of ASP015K under fasting conditions after single-dose administration between a test-tablet formulation and a reference-tablet formulation. This study will also evaluate the food effect on bioavailability of the test formulation, ...
What is the current status of trial NCT01929577?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2013-05. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01929577?
The interventions under investigation include: ASP015K (DRUG).
Who is sponsoring clinical trial NCT01929577?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.